precisionmedicineonline3d
FDA Approves New 'Vanza Triple' Cystic Fibrosis Drug From Vertex, Expands Label for Trikafta
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
precisionmedicineonline3d
BMS's Opdivo-Yervoy Combo Approved in Europe for First-Line Treatment of Certain Colorectal Cancers
The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
precisionmedicineonline3d
European Commission Approves AstraZeneca's Tagrisso in Unresectable EGFR-Mutated NSCLC
NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...
precisionmedicineonline6d
Institute for Follicular Lymphoma Innovation Invests $11M in PeproMene Bio's CAR T-Cell Therapy
R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.
precisionmedicineonline6d
Ultragenyx Submits BLA for Sanfilippo Syndrome Type A Gene Therapy, Seeks Accelerated Approval
The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.
precisionmedicineonline6d
Inceptor Bio Licenses Solid Tumor CAR T-Cell Therapy to Grit Bio in China
The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.